

## EQA round: E22/26 - Hormones 2

Deadline: 24.4.2026

Setup: groups - M (measurement principle), R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D <sub>max</sub> = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N <sub>tot</sub> = total number of the results		N <sub>eva</sub> = number of the results assessed
N <sub>out</sub> = number of the results removed before calculation		N <sub>suc</sub> = number of successful results
		S <sub>rel</sub> = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability					N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL			
<b>(393) C-peptide</b>	[pmol/L]				15							14	11	79
<b>Sample A</b>		471	200	42	15							14	11	79
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		267	9,6	3,6	5	0	CVPG	267	9	20%	213	321	5	
Other					10	0							9	
								1x 1/36, 3x 4/1, 4x 4/60, 2x 4/162						
<b>Sample B</b>		327	120	37	15							14	12	86
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		205	7,4	3,6	5	0	CVPG	206	4,7	20%	164	248	5	
Other					10	0							9	
								1x 1/36, 3x 4/1, 4x 4/60, 2x 4/162						
<b>(193) Ferritin</b>	[µg/L]				21							20	19	95
<b>Sample A</b>		38	8,2	22	21							20	20	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		39,9	2,8	7,1	6	0	CVPG	43,4	0,79	±16,8	26,6	60,2	6	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		29,7	2,4	8	6	0	CVPG	29,2	0,95	±16,8	12,4	46	6	
Other					9	0							8	
								3x 4/60, 3x 4/162, 1x 6/1, 1x 6/58, 1x 6/60						
<b>Sample B</b>		190	49	26	21							20	19	95
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		232	23	9,9	6	0	CVPG	234	4,9	24%	177	291	6	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		137	5,9	4,3	6	0	CVPG	135	4,5	24%	102	168	6	
Other					9	0							8	
								3x 4/60, 3x 4/162, 1x 6/1, 1x 6/58, 1x 6/60						
<b>(321) FSH</b>	[U/L]				15							15	15	100
<b>Sample A</b>		14,8	1,1	7,4	15							15	15	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		15,4	0,89	5,8	7	0	CVPG	15,8	0,34	15%	13,4	18,2	7	
Other					8	0							8	
								4x 4/1, 3x 4/60, 1x 4/162						
<b>Sample B</b>		14,1	1,1	7,8	15							15	15	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		14,7	1,5	10	7	0	CVPG	14,7	0,26	15%	12,4	17	7	
Other					8	0							8	
								4x 4/1, 3x 4/60, 1x 4/162						
<b>(328) hGH</b>	[mU/L]				8							8	8	100
<b>Sample A</b>		2,93	1	34	8							8	8	100
Other					8	0							8	
								1x 1/36, 3x 4/12, 2x 4/29, 2x 4/60						
<b>Sample B</b>		42	4,6	11	8							8	8	100
Other					8	0							8	
								1x 1/36, 3x 4/12, 2x 4/29, 2x 4/60						
<b>(329) IGF-1</b>	[µg/L]				5							4	4	100
<b>Sample A</b>		120	6,7	5,6	5							4	4	100
Other					5	0							4	
								1x 1/36, 3x 4/29, 1x 4/60						
<b>Sample B</b>		463	170	38	5							4	4	100
Other					5	0							4	
								1x 1/36, 3x 4/29, 1x 4/60						
<b>(392) IGF-BP3</b>	[µg/L]				2							2	2	100
<b>Sample A</b>		3460	540	16	2							2	2	100
Other					2	0							2	
								1x 4/29, 1x 4/60						
<b>Sample B</b>		3380	520	15	2							2	2	100
Other					2	0							2	
								1x 4/29, 1x 4/60						
<b>(325) Insulin</b>	[mU/L]				13							12	12	100
<b>Sample A</b>		14,5	2,1	14	13							12	12	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		13,7	0,5	3,7	6	0	CVPG	13,6	0,33	20%	10,8	16,4	6	
Other					7	0							6	
								1x 1/36, 3x 4/1, 1x 4/60, 2x 4/162						
<b>Sample B</b>		41	6,9	17	13							12	12	100

## EQA round: E22/26 - Hormones 2

Deadline: 24.4.2026

Setup: groups - M (measurement principle), R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability					N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]	
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter Other		38,4	2,5	6,4	6	0	CVPG	39,6	0,83	20%	31,6	47,6	6		
					7	0	1x 1/36, 3x 4/1, 1x 4/60, 2x 4/162					6			
<b>(326) Folate</b>	[nmol/L]				20								20	19	95
<b>Sample A</b>		50,1	6,2	12	20								20	19	95
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		45,3	0,015	0,03	7	0	CVPG	45,3	0,001	27%	33	57,6	7		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter Other		56,5	0,37	0,66	6	0	CVPG	53,2	1,3	27%	38,8	67,6	6		
					7	0	4x 4/60, 3x 4/162					7			
<b>Sample B</b>		50,5	6,8	14	20								20	19	95
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		45,3	0,015	0,03	7	0	CVPG	45,3	0,001	27%	33	57,6	7		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter Other		57,4	1,7	3	6	0	CVPG	54,8	1,5	27%	40	69,6	6		
					7	0	4x 4/60, 3x 4/162					7			
<b>(320) LH</b>	[U/L]				15								15	13	87
<b>Sample A</b>		7,38	1,4	19	15								15	13	87
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter Other		7,26	0,56	7,7	8	0	CVPG	7,29	0,13	15%	6,19	8,39	8		
					7	0	3x 4/1, 3x 4/60, 1x 4/162					7			
<b>Sample B</b>		3,39	0,69	20	15								15	14	93
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter Other		3,26	0,27	8,4	8	0	CVPG	3,27	0,061	15%	2,77	3,77	8		
					7	0	3x 4/1, 3x 4/60, 1x 4/162					7			
<b>(407) Parathyrin biointact (PTH 1-84)</b>	[pmol/L]				1								1	1	100
<b>Sample A</b>		0,71			1								1	1	100
Other					1	0	1x 4/60					1			
<b>Sample B</b>		1,53			1								1	1	100
Other					1	0	1x 4/60					1			
<b>(405) Parathyrin intact (PTH)</b>	[pmol/L]				17								17	15	88
<b>Sample A</b>		0,328	0,21	64	17								17	17	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter Other		0,174	0,053	31	9	0	CVPG	0,224	0,028 ± 0,276		0	0,5	9		
					8	0	2x 4/1, 1x 4/29, 3x 4/60, 2x 4/162					8			
<b>Sample B</b>		1,31	0,22	17	17								17	15	88
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter Other		1,18	0,1	8,8	9	0	CVPG	1,29	0,059	23%	0,993	1,59	9		
					8	0	2x 4/1, 1x 4/29, 3x 4/60, 2x 4/162					8			
<b>(322) Prolactin</b>	[mU/L]				15								14	13	93
<b>Sample A</b>		174	26	15	15								14	13	93
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter Other		162	7,8	4,8	6	0	CVPG	157	3,2	16%	131	183	6		
					9	0	1x 1/36, 2x 4/1, 4x 4/60, 2x 4/162					8			
<b>Sample B</b>		390	54	14	15								14	13	93
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter Other		372	11	2,9	6	0	CVPG	365	7,5	16%	306	424	6		
					9	0	1x 1/36, 2x 4/1, 4x 4/60, 2x 4/162					8			
<b>(390) Renin</b>	[ng/L]				4								2	2	100
<b>Sample A</b>		52,8	16	30	4								2	2	100
Other					4	0	1x 1/185, 1x 2/66, 1x 4/73, 1x 4/164					2			
<b>Sample B</b>		50,7	17	34	4								2	2	100
Other					4	0	1x 1/185, 1x 2/66, 1x 4/73, 1x 4/164					2			
<b>(394) SHBG</b>	[nmol/L]				6								6	5	83
<b>Sample A</b>		53,9	6,1	11	6								6	5	83
Other					6	0	1x 4/1, 2x 4/12, 3x 4/60					6			
<b>Sample B</b>		31,8	1,7	5,3	6								6	5	83

## EQA round: E22/26 - Hormones 2

Deadline: 24.4.2026

Setup: groups - M (measurement principle), R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability					N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL			
Other					6	0	1x 4/1, 2x 4/12, 3x 4/60					6		
<b>(327) Vitamin B<sub>12</sub></b>	[pmol/L]				19							19	19	100
<b>Sample A</b>		229	44	19	19							19	19	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		257	17	6,6	6	0	CVPG	244	4	20%	195	293	6	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		177	6,7	3,8	6	0	CVPG	178	4,2	20%	142	214	6	
Other					7	0	4x 4/60, 3x 4/162					7		
<b>Sample B</b>		237	46	19	19							19	19	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		253	12	4,9	6	0	CVPG	244	4,1	20%	195	293	6	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		181	11	6,2	6	0	CVPG	185	4,2	20%	148	222	6	
Other					7	0	4x 4/60, 3x 4/162					7		
<b>(319) Vitamin B<sub>12</sub> (active)</b>	[pmol/L]				5							5	5	100
<b>Sample A</b>		72,9	6,8	9,4	5							5	5	100
Other					5	0	3x 4/1, 2x 4/60					5		
<b>Sample B</b>		88,1	15	17	5							5	5	100
Other					5	0	3x 4/1, 2x 4/60					5		